Addressing Cardiovascular Toxicity Risk of Electronic Nicotine Delivery Systems in the Twenty-First Century: "What

Mark Chandy1, Thomas Hill2, Nerea Jimenez-Tellez3,4

  • 1Robarts Research Institute, Western University, London, N6A 5K8, Canada.

PubMed

Insights

Electronic nicotine delivery systems (ENDS) health effects on cardiovascular disease (CVD) remain unclear. This white paper explores new approach methodologies (NAMs) to assess ENDS cardiovascular toxicity and inform regulatory policy.

Area of Science:

  • Toxicology
  • Cardiovascular Science
  • Regulatory Science

Background:

  • Cigarette smoking is a known risk factor for cardiovascular disease (CVD).
  • Long-term cardiovascular health consequences of electronic nicotine delivery systems (ENDS) use are uncertain.
  • New Approach Methodologies (NAMs) offer rapid hazard prediction, considering biological factors like sex and race/ethnicity.

Purpose of the Study:

  • To evaluate current approaches for assessing ENDS cardiovascular toxicity.
  • To propose systems biology strategies to bridge knowledge gaps in ENDS risk assessment.
  • To inform regulatory policy for protecting public health from ENDS-related cardiovascular risks.

Main Methods:

  • Review of existing methods for evaluating tobacco product cardiovascular impacts.
  • Exploration of NAMs as alternatives to traditional animal testing for toxicity prediction.
  • Identification of data gaps and proposal of systems biology approaches.

Main Results:

  • Current methodologies for assessing ENDS cardiovascular toxicity are insufficient for regulatory decision-making.
  • NAMs show promise but have limitations in predicting complex human health outcomes.
  • A significant knowledge gap exists between traditional toxicological models and NAMs for ENDS.

Conclusions:

  • Standardized NAMs are needed to accurately predict ENDS cardiovascular toxicity.
  • Systems biology approaches can integrate data from various sources to enhance risk assessment.
  • Timely regulatory action requires robust data from validated NAMs to protect public health.

Related Concept Videos

Stimulants01:29

Stimulants

Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
192
Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants


Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.3K